elagolix + combined oral contraceptive

Elagolix + combined oral contraceptive is an investigational oral combination therapy being evaluated primarily for management of moderate to severe pain associated with endometriosis. **Elagolix** is a small molecule, oral, nonpeptide antagonist of the **gonadotropin-releasing hormone (GnRH) receptor**, which suppresses ovarian hormone production, reducing estrogen and progesterone levels and thereby decreasing endometriosis-associated pain. **Combined oral contraceptives (COC)** typically contain an estrogen (such as ethinyl estradiol) and a progestin (such as levonorgestrel), which inhibit ovulation, suppress gonadotropins, change cervical mucus and endometrium, and regulate menstrual cycles. The combination is being studied to assess whether COC provides additional benefits (such as cycle control or protection against bone loss) or adds to the safety/tolerability profile when taken with elagolix[5]. Elagolix is marketed for endometriosis as a monotherapy, but its safety and efficacy in combination with a COC are under investigation[5][3]. There are known **drug-drug interactions**: co-administration may increase ethinyl estradiol exposure and decrease levonorgestrel exposure, potentially increasing the risk of estrogen-related adverse events (e.g., thromboembolism)[3]. Nonhormonal contraception is recommended during elagolix treatment with or without a combined oral contraceptive[3][6][7].

Other names

elagolix + COCelagolix in combination with combined oral contraceptives